Serum Soluble Corin and Long‐Term Clinical Outcomes After Acute Ischemic Stroke

Abstract

Background Corin plays important roles in the regulation of blood volume and pressure and cardiac function by activating natriuretic peptide pathway, exerting multiple cardioprotective effects. But the impacts of soluble corin on clinical outcomes after ischemic stroke are unclear. We aimed to investigate the associations between serum soluble corin and long‐term clinical outcomes after acute ischemic stroke. Methods and Results We measured the concentrations of serum soluble corin in 3162 participants (2010 men and 1152 women) from the China Antihypertensive Trial in Acute Ischemic Stroke. The clinical outcomes were recurrent stroke, cardiovascular events, all‐cause mortality, and unfavorable functional outcome within 24 months after stroke. Risk reclassification for study clinical outcomes of models with soluble corin were evaluated. Serum soluble corin was inversely associated with recurrent stroke, cardiovascular events, and unfavorable functional outcome after ischemic stroke. After adjusting for multiple covariates, each additional SD of log‐corin was associated with a 21% (95% CI, 11–30), 16% (95% CI, 6–26), and 12% (95% CI, 3–21) decreased risk for recurrent stroke, cardiovascular events, and unfavorable functional outcome, respectively. Furthermore, the addition of soluble corin to the basic model with conventional risk factors significantly improved risk discrimination for recurrent stroke, cardiovascular events, and the composite outcome of all‐cause mortality and cardiovascular events, as shown by C‐statistics (all P<0.05). Conclusions Serum soluble corin was associated with decreased risks of long‐term clinical outcomes, and may be a promising prognostic biomarker for risk stratification in patients with acute ischemic stroke.

Keywords

• cardiovascular events
• ischemic stroke
• prognosis
• recurrent stroke
• soluble corin